Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 9/20 | 1.00 |
| ▸ | TNF | P01375 | 4/20 | 0.64 |
| ▸ | ACHE | P22303 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | PDE4A | P27815 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanidine SCHEMBL8402439 | 0.93 | ADORA2B (0.87) | ADORA2BTNFACHEUSP2LMNA | |
| Trolamine SCHEMBL9792228 | 0.90 | ADORA2B (0.81) | ADORA2BTNFACHEUSP2LMNA | |
| SCHEMBL20863739 | 0.88 | ADORA2B (1.00) | ADORA2BTNFACHEUSP2LMNA | |
| SCHEMBL2830735 | 0.88 | ADORA2B (0.79) | ADORA2BTNFACHEUSP2LMNA | |
| SCHEMBL6861215 | 0.87 | ADORA2B (0.77) | ADORA2BTNFACHEUSP2LMNA | |
| SCHEMBL8570022 | 0.87 | ADORA2B (0.77) | ADORA2BTNFACHEUSP2LMNA | |
| SCHEMBL10407732 | 0.86 | ADORA2B (0.75) | ADORA2BTNFACHEUSP2LMNA | |
| SCHEMBL10407724 | 0.86 | ADORA2B (0.75) | ADORA2BTNFACHEUSP2LMNA | |
| SCHEMBL10407485 | 0.86 | ADORA2B (0.75) | ADORA2BTNFACHEUSP2LMNA | |
| SCHEMBL4316404 | 0.86 | ADORA2B (0.75) | ADORA2BTNFACHEUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115028594-A | Emotitabine medicinal precursor compound and preparation method and medical application thereof | 吴卫东 | 2022-09-09 | — | — | CN | claimed |
| CN-111110590-B | Agar oligosaccharide composition for balancing scalp grease secretion, preparation method and application | 厦门传茗生物科技有限公司 | 2022-06-28 | — | — | CN | claimed |
| CN-114621156-A | Entifovir pharmaceutical precursor compound, preparation method and medical application thereof | 吴卫东 | 2022-06-14 | — | — | CN | claimed |
| WO-2021048794-A1 | EMULSIFIABLE CAFFEINE CARBOXYLATE CONCENTRATES | SUMINISTROS DE COLOMBIA S.A.S. - SUMICOL (CO) | 2021-03-18 | — | — | WO | claimed |
| CN-111110590-A | Agar oligosaccharide composition for balancing scalp grease secretion, preparation method and application | 蓝脑科技(厦门)有限公司 | 2020-05-08 | — | — | CN | claimed |
| CN-105579020-B | Formulations comprising sphingosine | 赢创德固赛有限公司 | 2020-01-07 | — | — | CN | claimed |
| CN-109589298-A | A kind of artemia eggs ghost dispersion liquid and its preparation process and application | 水母娘娘海洋生物科技有限公司 | 2019-04-09 | — | — | CN | claimed |
| EP-2170259-B1 | SLIMMING COMPOSITION | BASF BEAUTY CARE SOLUTIONS FRANCE SAS (FR) | 2018-09-05 | — | — | EP | claimed |
| US-9962329-B2 | Cosmetic use of the combination of a carob germ extract and caffeine as a slimming active agent | ISP Investments, LLC (US) | 2018-05-08 | — | — | US | claimed |
| US-9913789-B2 | Formulations containing sphinganine | EVONIK DEGUSSA GMBH (DE) | 2018-03-13 | — | — | US | claimed |
| US-8506935-B2 | Respiratory drug condensation aerosols and methods of making and using them | ALEXZA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | claimed |
| US-20090258075-A1 | Respiratory Drug Condensation Aerosols and Methods of Making and Using Them | ALEXZA PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | claimed |
| US-7550133-B2 | Respiratory drug condensation aerosols and methods of making and using them | ALEXZA PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | claimed |
| US-20040105819-A1 | comprise respiratory drug condensation aerosol particles; selected from the group consisting of beta -adrenergics, methylxanthines, anticholinergics, corticosteroids, mediator-release inhibitors, anti-leukotriene drugs, asthma inhibitors etc | ALEXZA MOLECULAR DELIVERY CORPORATION (US) | 2004-06-03 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5030451-A | Micronizing binder support into scales, micronizing active principle particles, mixing, wetting agent, agglomeration, drying, screening, hydroalcoholic gel | PIERRE FABRE S.A. (FR) | 1991-07-09 | — | — | US | claimed |
| EP-0191624-A2 | Gold-purine antitumor agents | ENGELHARD CORPORATION (US) | 1986-08-20 | — | — | EP | claimed |
| EP-0051278-A1 | Soft tertiary amine esters of bio-affecting carboxylic acids, processes for preparing and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1982-05-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258075-A1 | Respiratory Drug Condensation Aerosols and Methods of Making and Using Them | LTC4S, PTGER1, PTGES | ADORA2B 290/4885TNF 374/4885ACHE 159/4885 |
| US-20040105819-A1 | comprise respiratory drug condensation aerosol particles; selected from the group consisting of beta -adrenergics, methylxanthines, anticholinergics, corticosteroids, mediator-release inhibitors, anti-leukotriene drugs, asthma inhibitors etc | LTC4S, PTGER1, PTGER4 | ADORA2B 165/4885TNF 565/4885ACHE 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.